• <center id="my6c6"></center>
    <rt id="my6c6"><acronym id="my6c6"></acronym></rt>
  • <abbr id="my6c6"></abbr>
  •  

    上海強世信息科技有限公司

    Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies
    作者: | 發布:Ying C Ou, Lucy Liu , Kun Wang ,Yuying Gao,etal. | 發布時間: 2021-03-31 | 535 次瀏覽 | 分享到:
    Abstract

    Zanubrutinib is a potent, second-generation Bruton's tyrosine kinase inhibitor that is currently being investigated in patients with B-cell malignancies and recently received accelerated approval in the United States for treatment of relapsed/refractory mantle cell lymphoma. The objective of this analysis was to develop a population pharmacokinetic (PK) model to characterize the PKs of zanubrutinib and identify the potential impact of intrinsic and extrinsic covariates on zanubrutinib PK. Data across nine clinical studies of patients with B-cell malignancies and data of healthy volunteers (HVs) were included in this analysis, at total daily doses ranging from 20 to 320 mg. In total, 4,925 zanubrutinib plasma samples from 632 subjects were analyzed using nonlinear mixed-effects modeling. Zanubrutinib PKs were adequately described by a two-compartment model with sequential zero-order then first-order absorption, and first-order elimination. A time-dependent residual error model was implemented in order to better capture the observed maximum concentration variability in subjects. Baseline alanine aminotransferase and health status (HVs or patients with B-cell malignancies) were identified as statistically significant covariates on the PKs of zanubrutinib. These factors are unlikely to be clinically meaningful based on a sensitivity analysis. No statistically significant differences in the PKs of zanubrutinib were observed based on age, sex, race (Asian, white, and other), body weight, mild or moderate renal impairment (creatinine clearance ≥ 30 mL/minute as estimated by Cockcroft-Gault), baseline aspartate aminotransferase, bilirubin, tumor type, or use of acid-reducing agents (including proton pump inhibitors). These results support that no dose adjustment is considered necessary based on the aforementioned factors.

     Clin Transl Sci, 2021 Mar;14(2) 764-772.


    https://pubmed.ncbi.nlm.nih.gov/33306268/


    成人国内精品久久久久一区| 色综合久久综合网| 亚洲精品二三区伊人久久| 2022久久国产精品免费热麻豆| 91久久精品国产成人久久| 久久精品日韩一区国产二区| 国产成人久久精品麻豆一区| 91精品国产乱码久久久久久 | 久久精品夜色噜噜亚洲A∨| 久久中文字幕一区二区| 人妻丰满AV无码久久不卡 | 久久国产真实乱对白| 国产亚洲色婷婷久久99精品| 久久婷婷五月综合97色一本一本| 国产精品夜夜春夜夜爽久久小| 亚洲国产精品婷婷久久| 国产一级持黄大片99久久| yy6080久久亚洲精品| 久久狠狠躁免费观看2020| 久久精品国产亚洲AV天海翼| 久久精品九九亚洲精品| 久久亚洲国产精品五月天婷| 国产成人综合久久精品免费| 一本久久久久久久| 久久精品国产亚洲AV麻豆不卡| 久久中文字幕视频、最近更新| 国产精品青草久久| 久久久无码精品人妻一区| 精品国产乱码久久久久久1区2区 | 97久久精品国产成人影院| 日本一区精品久久久久影院| 久久午夜福利电影| 久久精品国产WWW456C0M| 精品久久久无码21p发布| 久久亚洲精精品中文字幕| 久久国产精品系列| 亚洲精品无码久久久久AV麻豆| 日本久久久免费高清| 久久精品国产亚洲av日韩| 久久综合给合久久狠狠狠97色| 久久久久久久久久久福利|